Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095231 Target Snapshot

Hepatitis C virus serine protease, NS3/NS4A · PROTEIN COMPLEX · Hepatitis C virus

Back to Search Search this target Browse approvals Evidence Card
874Compounds
106Assays
7Approved Drugs
1,180.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Hepatitis C virus serine protease, NS3/NS4A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 16 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt D2K2A8. Start with chronic hepatitis C virus infection, then reuse UniProt D2K2A8 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic hepatitis C virus infection, then reuse UniProt D2K2A8 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 16 linked drugs
Open source guide
Disease program
chronic hepatitis C virus infection

Hepatitis C virus serine protease, NS3/NS4A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 16 linked drugs remain visible in the same block.

Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include ASUNAPREVIR, BOCEPREVIR, DANOPREVIR, FALDAPREVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 16 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis C virus serine protease, NS3/NS4A as ChEMBL target CHEMBL2095231, mapped to UniProt D2K2A8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis C virus serine protease, NS3/NS4A
PROTEIN COMPLEX · Hepatitis C virus
As of 2026-09-13
ChEMBL target ID
CHEMBL2095231
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
D2K2A8
Non-structural protein 4A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatitis C virus serine protease, NS3/NS4A is the right protein anchor across sources, using UniProt D2K2A8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic hepatitis C virus infection is currently framed as approved-linked support. It currently carries 16 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHepatitis C virus serine protease, NS3/NS4A
Target TypePROTEIN COMPLEX
OrganismHepatitis C virus
UniProtD2K2A8
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNon-structural protein 4A
UniProt AccessionD2K2A8
Component TypeProtein
Sequence Length54 aa

Non-structural protein 4A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Hepatitis C virus serine protease, NS3/NS4A, mapped to UniProt D2K2A8. ChEMBL maps the protein component as Non-structural protein 4A. Sequence length is 54 aa.

Mapped IDD2K2A8
Review nameHepatitis C virus serine protease, NS3/NS4A
OrganismHepatitis C virus
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Hepatitis C virus serine protease, NS3/NS4A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
chronic hepatitis C virus infection
16 linked drugs · 16 direct · 16 efficacy
Linked drugASUNAPREVIR
Linked drugBOCEPREVIR
Linked drugDANOPREVIR
Linked drugFALDAPREVIR
Approved-linked Approved
hepatitis C virus infection
14 linked drugs · 14 direct · 14 efficacy
Linked drugASUNAPREVIR
Linked drugBOCEPREVIR
Linked drugDANOPREVIR
Linked drugFALDAPREVIR
Approved-linked Approved
viral disease
5 linked drugs · 5 direct · 5 efficacy
Linked drugASUNAPREVIR
Linked drugBOCEPREVIR
Linked drugFALDAPREVIR
Linked drugNARLAPREVIR
Late clinical Phase III
infection
3 linked drugs · 3 direct · 3 efficacy
Linked drugASUNAPREVIR
Linked drugTELAPREVIR
Linked drugVANIPREVIR
Late clinical Phase III
HIV infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugFALDAPREVIR
Linked drugTELAPREVIR
Clinical signal Phase II
Thrombocytopenia
2 linked drugs · 2 direct · 2 efficacy
Linked drugBOCEPREVIR
Linked drugTELAPREVIR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include ASUNAPREVIR, BOCEPREVIR, DANOPREVIR, FALDAPREVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic hepatitis C virus infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
5
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

IC50618.0
KI500.0
EC5062.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL349186 11.0 Ki 0.01 Preclinical
CHEMBL3785323 11.0 IC50 0.01 Preclinical
CHEMBL2063090 11.0 IC50 0.01 Approved
CHEMBL2063089 10.7 Ki 0.02 Preclinical
CHEMBL3928647 10.7 IC50 0.02 Preclinical
CHEMBL3924454 10.52 IC50 0.03 Preclinical
CHEMBL3943429 10.4 IC50 0.04 Preclinical
CHEMBL3786672 10.34 IC50 0.046 Preclinical
CHEMBL3915464 10.3 IC50 0.05 Preclinical
CHEMBL3893915 10.3 IC50 0.05 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
55
5.5
109
6.0
107
6.5
124
7.0
137
7.5
183
8.0
169
8.5
61
9.0
27
9.5
pChEMBL
Approved Drugs

Approved Drugs

GLECAPREVIR
CHEMBL3545363
Approved 2017
Properties Compare Identifier
GRAZOPREVIR ANHYDROUS
CHEMBL2063090
Approved 2016
Properties Compare Identifier
ASUNAPREVIR
CHEMBL2105735
Approved 2014
Properties Compare Identifier
SIMEPREVIR
CHEMBL501849
Approved 2013
Properties Compare Identifier
TELAPREVIR
CHEMBL231813
Approved 2011
Properties Compare Identifier
BOCEPREVIR
CHEMBL218394
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

106
Total Assays
831
Tested Compounds
1
Assay Types
Binding — 106 assays, 831 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 76 526 7.2
assay format 18 266 8.1
single protein format 8 38 7.2
cell-based format 4 1 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine